<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03610347</url>
  </required_header>
  <id_info>
    <org_study_id>PEBSI-2</org_study_id>
    <nct_id>NCT03610347</nct_id>
  </id_info>
  <brief_title>Paclitaxel Eluting Balloon After Bare Metal Stent Implantation vs. Drug-Eluting Stent in St Elevation Myocardial Infarction</brief_title>
  <acronym>PEBSI-2</acronym>
  <official_title>Study to Evaluate the Efficacy and Safety of Paclitaxel Eluting Balloon After Bare Metal Stent Implantation Versus Drug-eluting Stent in St Elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion Investigacion Interhospitalaria Cardiovascular</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Effice Servicios Para la Investigacion S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacion Investigacion Interhospitalaria Cardiovascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study objective is the evaluation of safety and efficacy at 12 months of the combination
      treatment of bare metal Stent plus Paclitaxel Eluting Balloon vs drug eluting stent in
      patients with ST-elevation myocardial infarction with less than 12 hours of evolution.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, prospective, randomized, open study

      After the permeabilization of the clinical event responsible artery patients will be
      randomized in a 1:1 ratio to one of the following treatment groups:

      Group 1: insertion of a bare metal stent with post-dilatation with a paclitaxel eluting
      balloon (Pantera Lux ®)

      Group 2: insertion of a drug elution stent

      Patients (or their legal representative) must sign the consent before randomization.

      Patients will be monitored 30 days after surgery, at 6 and 12 months.

      The primary efficacy endpoint is Target Vessel Failure (TVF) at 12 months

      This study will involve patients over 18 years old with STEMI, or new left bundle branch
      block or posterior AMI (ECG) that occur within 12 hours of onset of symptoms.

      A total of 516 patients will be included.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low recruitment
  </why_stopped>
  <start_date type="Actual">June 29, 2016</start_date>
  <completion_date type="Actual">March 31, 2020</completion_date>
  <primary_completion_date type="Actual">January 28, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target Vessel Failure (TVF)</measure>
    <time_frame>1 year</time_frame>
    <description>Efficacy: TVF define as a the composite of cardiac death, target-vessel myocardial infarction, or ischemia-driven target-lesion revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR)</measure>
    <time_frame>1 year</time_frame>
    <description>Efficacy: ischemia-driven target-lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>1 year</time_frame>
    <description>Safety: Major Adverse Cardiac Events (MACE) at 12 months (death, re-infarction, acute cardiovascular disease, hemorrhagy and/or stent thrombosis).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Angiographic Substudy</measure>
    <time_frame>9 months</time_frame>
    <description>QCA late loss</description>
  </other_outcome>
  <other_outcome>
    <measure>Optical Coherence Tomography (OCT) Substudy</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Stent struts coverage by intravascular OCT</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">199</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Bare metal Stent plus Paclitaxel Balloon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional bare metal Stent plus Paclitaxel Eluting Balloon(Pantera Lux®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug-Eluting Stent (DES)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sirolimus Eluting Stent (Orsiro®)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bare metal Stent plus Paclitaxel Balloon</intervention_name>
    <arm_group_label>Bare metal Stent plus Paclitaxel Balloon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug Eluting Stent</intervention_name>
    <arm_group_label>Drug-Eluting Stent (DES)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged equal or older than 18 years.

          -  Acute myocardial infarction (AMI) within 12 hours of evolution (from the onset of
             symptoms) systolic time elevation of at least 1 mm (recorded in two or more contiguous
             leads), new left bundle branch block, or true posterior infarction.

          -  Patients candidates for primary angioplasty as medical criteria

          -  Written informed consent according to International Conference on Harmonization /
             Guide Clinical Practice and local legislation, obtained before any study procedure.

          -  Diameter vascular coronary artery to treat between 2 mm and 4 mm.

          -  Patients with 85-100% stenosis and TIMI Score (Thrombolysis In Myocardial Infarction)
             of 0-I.

        Exclusion Criteria:

          -  Patients who refuse to participate in the study

          -  Cardiogenic shock (defined as systolic blood pressure less than 80 mm Hg for more than
             30 minutes or need for vasopressors or intra-aortic balloon counterpulsation)

          -  Concomitant diseases associated with a life expectancy of less than one year

          -  Angiographic variables:

               -  Trunk unprotected

               -  Branching (side branch greater than 2.5 mm)

               -  Sinus tachycardia segment elevation myocardial infarction thrombosis secondary to
                  stent

               -  If more than one stent to treat a single segment (overlapping stents)

               -  Patient candidate for surgical revascularization within 30 days

               -  Stenosis of greater than 30 mm in length (corresponding with the ball longer
                  available)

               -  More severe stenosis in the same artery in which is expected to be addressed in
                  the next 9 months

          -  Women at childbearing age, where there is the possibility of pregnancy during the
             first year of follow-up, or nursing.

          -  Any clinical condition, which in the opinion of the investigator, is considered
             clinically significant as to participate in the study.

          -  Subjects who are participating in any study drug or medical.

          -  Individuals who show inability to follow instructions or help during the course of the
             study.

          -  Bleeding diathesis or other disorders such as gastrointestinal ulceration or cerebral
             circulatory disorders, restricting the use of treatments platelet aggregation
             inhibitors and anticoagulants.

          -  Patients with an ejection fraction &lt;30% (if known).

          -  Allergy or hypersensitivity to paclitaxel intolerance, or compounds structurally
             related to the Butyryl tri-n-hexyl citrate (BTHC) matrix of administration.

          -  Severe allergy to contrast media.

          -  Coronary artery spasm in the absence of significant stenosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>H. U. Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Baleares</state>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. U. Puerto Real</name>
      <address>
        <city>Puerto Real</city>
        <state>Cádiz</state>
        <zip>11510</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. U. de Bellvitge</name>
      <address>
        <city>L'Hospitalet De Llobregat</city>
        <state>H. U. De Bellvitge</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario U. de Albacete</name>
      <address>
        <city>Albacete</city>
        <zip>05200</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. U. Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Clínic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. General U. de Ciudad Real</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. U. Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. U. de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. U. 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. U. Puerta de Hierro Majadahonda</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Regional U. de Málaga</name>
      <address>
        <city>Málaga</city>
        <zip>29011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. U. i Politècnic La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Clínico U. de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 26, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2018</study_first_posted>
  <last_update_submitted>May 21, 2020</last_update_submitted>
  <last_update_submitted_qc>May 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion Investigacion Interhospitalaria Cardiovascular</investigator_affiliation>
    <investigator_full_name>Arturo García-Touchard</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

